Skip to main content
SpringerLink
Log in

Splenectomy followed by administration of rituximab is useful to treat a patient with hairy cell leukemia-variant

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Swerdlow SH, Campo E, Harris NL et al (2008) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. International Agency for Research on Cancer, Lyon

    Google Scholar 

  2. Hockley SL, Else M, Morilla A et al (2012) The prognostic impact of clinical and molecular features in hairy cell leukaemia variant and splenic marginal zone lymphoma. Br J Haematol 158:347–354

    Article  PubMed  CAS  Google Scholar 

  3. Robak T (2011) Hairy-cell leukemia variant: recent view on diagnosis, biology and treatment. Cancer Treat Rev 37:3–10

    Article  PubMed  Google Scholar 

  4. Jones G, Parry-Jones N, Wilkins B et al (2011) Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant. Br J Haematol 156:186–195

    Article  PubMed  Google Scholar 

  5. Narat S, Gandla J, Dogan A, Mehta A (2005) Successful treatment of hairy cell leukemia variant with rituximab. Leuk Lymphoma 46:1229–1232

    Article  PubMed  CAS  Google Scholar 

  6. Quach H, Januszewicz H, Westerman D (2005) Complete remission of hairy cell leukemia variant (HCL-v) complicated by red cell aplasia post treatment with rituximab. Haematologica 90:e72–e73

    Google Scholar 

  7. Grever MR (2010) How I treat hairy cell leukemia. Blood 115:21–28

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

We thank Sachiko Fukumoto and Nanae Nakaju for technical assistance.

Conflicts of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8553, Japan

    Tetsumi Yoshida, Keichiro Mihara, Sayaka Sugihara & Tatsuji Mino

  2. Department of Pathology, Hiroshima University, Hiroshima, Japan

    Koji Arihiro

  3. Department of Pathology, Kure Kyosai Hospital, Kure, Japan

    Naomi Sasaki

  4. Department of Stem Cell Biology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan

    Yoshihiro Takihara

Authors
  1. Tetsumi Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Keichiro Mihara
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sayaka Sugihara
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Koji Arihiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tatsuji Mino
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Naomi Sasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yoshihiro Takihara
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Keichiro Mihara.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yoshida, T., Mihara, K., Sugihara, S. et al. Splenectomy followed by administration of rituximab is useful to treat a patient with hairy cell leukemia-variant. Ann Hematol 92, 711–713 (2013). https://doi.org/10.1007/s00277-012-1612-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-012-1612-1

Keywords

Search

Navigation